234 related articles for article (PubMed ID: 7956274)
1. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group.
Dhainaut JF; Tenaillon A; Le Tulzo Y; Schlemmer B; Solet JP; Wolff M; Holzapfel L; Zeni F; Dreyfuss D; Mira JP
Crit Care Med; 1994 Nov; 22(11):1720-8. PubMed ID: 7956274
[TBL] [Abstract][Full Text] [Related]
2. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group.
Dhainaut JF; Tenaillon A; Hemmer M; Damas P; Le Tulzo Y; Radermacher P; Schaller MD; Sollet JP; Wolff M; Holzapfel L; Zeni F; Vedrinne JM; de Vathaire F; Gourlay ML; Guinot P; Mira JP
Crit Care Med; 1998 Dec; 26(12):1963-71. PubMed ID: 9875905
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of the Platelet-Activating Factor Receptor Antagonist BN 52021 (Ginkgolide B) in Patients with Severe Sepsis : A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial.
Albrecht DM; van Ackern K; Bender HJ; Hof H; Kox W; Victor N; Funk P; Kieser M; Köhler S; Krausch D; Marzi I; Menges T; Schmidt H
Clin Drug Investig; 2004; 24(3):137-47. PubMed ID: 17516700
[TBL] [Abstract][Full Text] [Related]
4. Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis.
Vincent JL; Spapen H; Bakker J; Webster NR; Curtis L
Crit Care Med; 2000 Mar; 28(3):638-42. PubMed ID: 10752807
[TBL] [Abstract][Full Text] [Related]
5. Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial.
Schuster DP; Metzler M; Opal S; Lowry S; Balk R; Abraham E; Levy H; Slotman G; Coyne E; Souza S; Pribble J;
Crit Care Med; 2003 Jun; 31(6):1612-9. PubMed ID: 12794395
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.
Abraham E; Wunderink R; Silverman H; Perl TM; Nasraway S; Levy H; Bone R; Wenzel RP; Balk R; Allred R
JAMA; 1995 Mar 22-29; 273(12):934-41. PubMed ID: 7884952
[TBL] [Abstract][Full Text] [Related]
7. Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group.
Poeze M; Froon AH; Ramsay G; Buurman WA; Greve JW
Shock; 2000 Oct; 14(4):421-8. PubMed ID: 11049104
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.
Tidswell M; Tillis W; Larosa SP; Lynn M; Wittek AE; Kao R; Wheeler J; Gogate J; Opal SM;
Crit Care Med; 2010 Jan; 38(1):72-83. PubMed ID: 19661804
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial.
Opal S; Laterre PF; Abraham E; Francois B; Wittebole X; Lowry S; Dhainaut JF; Warren B; Dugernier T; Lopez A; Sanchez M; Demeyer I; Jauregui L; Lorente JA; McGee W; Reinhart K; Kljucar S; Souza S; Pribble J;
Crit Care Med; 2004 Feb; 32(2):332-41. PubMed ID: 14758145
[TBL] [Abstract][Full Text] [Related]
10. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group.
Fein AM; Bernard GR; Criner GJ; Fletcher EC; Good JT; Knaus WA; Levy H; Matuschak GM; Shanies HM; Taylor RW; Rodell TC
JAMA; 1997 Feb; 277(6):482-7. PubMed ID: 9020273
[TBL] [Abstract][Full Text] [Related]
11. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.
Abraham E; Glauser MP; Butler T; Garbino J; Gelmont D; Laterre PF; Kudsk K; Bruining HA; Otto C; Tobin E; Zwingelstein C; Lesslauer W; Leighton A
JAMA; 1997 May; 277(19):1531-8. PubMed ID: 9153367
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial.
Dellinger RP; Tomayko JF; Angus DC; Opal S; Cupo MA; McDermott S; Ducher A; Calandra T; Cohen J;
Crit Care Med; 2009 Nov; 37(11):2929-38. PubMed ID: 19770753
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure.
Abraham E; Naum C; Bandi V; Gervich D; Lowry SF; Wunderink R; Schein RM; Macias W; Skerjanec S; Dmitrienko A; Farid N; Forgue ST; Jiang F
Crit Care Med; 2003 Mar; 31(3):718-28. PubMed ID: 12626975
[TBL] [Abstract][Full Text] [Related]
14. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial.
Fisher CJ; Slotman GJ; Opal SM; Pribble JP; Bone RC; Emmanuel G; Ng D; Bloedow DC; Catalano MA;
Crit Care Med; 1994 Jan; 22(1):12-21. PubMed ID: 8124953
[TBL] [Abstract][Full Text] [Related]
15. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group.
Bone RC; Balk RA; Fein AM; Perl TM; Wenzel RP; Reines HD; Quenzer RW; Iberti TJ; Macintyre N; Schein RM
Crit Care Med; 1995 Jun; 23(6):994-1006. PubMed ID: 7774238
[TBL] [Abstract][Full Text] [Related]
16. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.
Opal SM; Fisher CJ; Dhainaut JF; Vincent JL; Brase R; Lowry SF; Sadoff JC; Slotman GJ; Levy H; Balk RA; Shelly MP; Pribble JP; LaBrecque JF; Lookabaugh J; Donovan H; Dubin H; Baughman R; Norman J; DeMaria E; Matzel K; Abraham E; Seneff M
Crit Care Med; 1997 Jul; 25(7):1115-24. PubMed ID: 9233735
[TBL] [Abstract][Full Text] [Related]
17. Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock.
Angstwurm MW; Engelmann L; Zimmermann T; Lehmann C; Spes CH; Abel P; Strauss R; Meier-Hellmann A; Insel R; Radke J; Schüttler J; Gärtner R
Crit Care Med; 2007 Jan; 35(1):118-26. PubMed ID: 17095947
[TBL] [Abstract][Full Text] [Related]
18. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis.
Eisele B; Lamy M; Thijs LG; Keinecke HO; Schuster HP; Matthias FR; Fourrier F; Heinrichs H; Delvos U
Intensive Care Med; 1998 Jul; 24(7):663-72. PubMed ID: 9722035
[TBL] [Abstract][Full Text] [Related]
19. Effects of the platelet-activating factor receptor antagonist BN 52021 on hematologic variables and blood loss during and after cardiopulmonary bypass.
Nathan N; Mercury P; Denizot Y; Cornu E; Laskar M; Arnoux B; Feiss P
Anesth Analg; 1994 Aug; 79(2):205-11. PubMed ID: 7639352
[TBL] [Abstract][Full Text] [Related]
20. Effect of the antiendotoxic agent, taurolidine, in the treatment of sepsis syndrome: a placebo-controlled, double-blind trial.
Willatts SM; Radford S; Leitermann M
Crit Care Med; 1995 Jun; 23(6):1033-9. PubMed ID: 7774213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
